Olema Oncology
Mr. Kovacs joined Olema in June 2020 as Chief Operating and Financial Officer bringing strong biotech operating, strategic advisory and capital markets experience, including at BlueRock Therapeutics LP, where he was Chief Business and Financial Officer. Previous positions include Managing Director, Head of Biotechnology Investment Banking at RBC Capital Markets; Executive Vice President, Chief Financial Officer, Head of Corporate Development and Director of PTC Therapeutics International; and Managing Director, Healthcare Investment Banking, at Credit Suisse. Mr. Kovacs is responsible for the finance, communications, human resources and information technology functions of the company. He received a B.Eng. in chemical engineering and a B.S. in life sciences from Queen’s University and an M.B.A. from the University of Western Ontario. He is also a CFA charterholder.
This person is not in any offices
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.